Today: 4 March 2026
Subscribe
Browse Category

Stock Market 18 October 2025

BigBear.ai (BBAI) Stock Rockets 80% in 2025 – Is the Defense-AI Rally Just Beginning?

BigBear.ai’s Stock Skyrockets on Defense AI Deals – Is BBAI the Next Palantir? 🚀

BigBear.ai shares jumped 22% on Oct. 13 after announcing a military AI partnership, reaching $9 before closing at $7.42 on Oct. 17. The company secured new U.S. defense contracts but reported Q2 revenue down 18% to $32.5 million and a net loss of $228.6 million. Wall Street rates the stock Hold, with a $6 average target. BigBear ended Q2 with $390 million in cash and a $380 million backlog.
18 October 2025
···
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Atai Life Sciences shares surged 18% to close near $6.45 on Oct. 17, 2025, after the FDA granted Breakthrough Therapy status to its experimental depression nasal spray BPL-003. The company raised $130 million in a public offering at $5.48 per share. Analysts issued strong Buy ratings with targets up to $15. ARK Invest disclosed buying about 250,000 shares.
18 October 2025
·
Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco Stock Surges Near 52-Week High on AI Momentum – What’s Next for CSCO?

Cisco Systems shares traded near $69–$70 on Oct. 17, 2025, close to a 52-week high and up about 30% over 12 months. The company reported Q4 earnings of $0.99 per share on $14.67 billion revenue, beating forecasts, and guided for 5–6% revenue growth in FY2026. Cisco launched new AI-focused products in October, with early orders from Microsoft and Alibaba. Market cap stands at roughly $270 billion.
18 October 2025
···
New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy & Digital (NASDAQ: NUAI) closed at $4.55 on Oct. 17, up 44% for the day and 186% in two weeks, after announcing progress on its Texas AI data center project. The company regained Nasdaq compliance, ended plans for a new share sale, and now claims to be sufficiently funded. Market cap stands near $129 million. New Era remains pre-revenue, with heavy trading volume and ongoing volatility.
18 October 2025
···
MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed shares hit a 52-week high of $13.09 on Oct. 14, up 68% year-to-date, after its LSD-derived drug MM120 showed 48% remission in a Phase 2b anxiety trial and received FDA Breakthrough Therapy status. The company holds $237.9 million in cash and is running three Phase 3 studies, with topline results due in 2026. Most analysts rate MNMD a “Moderate Buy” with an average 12-month target near $28.
18 October 2025
·
Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

Virgin Galactic (SPCE) Stock Rockets 40% Then Reverses – What’s Fueling the Space Tourism Frenzy?

Virgin Galactic shares fell 7.9% to $4.08 on Oct. 18 after spiking over 40% earlier in the month, driven by heavy trading and high short interest. Q2 2025 revenue dropped to $0.4 million, with a net loss of $67 million. The company holds $508 million in cash, targeting late 2026 for its new Delta Class spaceplane’s first flight. Wall Street consensus is Neutral, with price targets recently cut to $2–$2.50 by some analysts.
18 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat Stock Implodes: 60% Crash After Shocking Debt-For-Equity Swap

Beyond Meat shares plunged nearly 60% intraday on Oct. 13, 2025, closing at about $0.67 by Oct. 15—near record lows. The company swapped 96.9% of its 2027 convertible debt for $208.7 million in new notes and 316.15 million new shares, heavily diluting equity. Founder/CEO Ethan Brown and CFO Nandita Bakhshi resigned from the board. Analyst ratings remain strongly negative, with short interest at record highs.
18 October 2025
·
Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy (LBRT) Stock Surges 28% After Q3 Earnings – What’s Next?

Liberty Energy shares surged 28% to $15.32 on Oct. 17 after Q3 results, rebounding from a prior close of $11.94. Revenue fell 17% to $947 million, with an adjusted EPS loss of $0.06, but GAAP net income reached $43 million due to one-time gains. Management raised the dividend 13%. Despite the rally, the stock remains well below last year’s $23.58 high.
18 October 2025
···
Virgin Galactic Rockets 15% on Space Tourism Buzz – Can SPCE Defy Gravity or Crash Back to Earth?

Virgin Galactic’s Wild October Ride: SPCE Stock Soars on Space Tourism Hype, Then Plummets – What’s Next?

Virgin Galactic shares fell nearly 8% on Oct. 17 to $4.08 after a mid-month rally, leaving the stock down about 33% in 2025 and 99% below all-time highs. The company settled a shareholder lawsuit for $2.9 million in September. It announced a 2027 suborbital research flight with Purdue University. Virgin Galactic reported a $67 million Q2 loss and has about 1.5 years of cash left.
18 October 2025
··
Beyond Meat’s Shocking Collapse: BYND Stock Crashes Below $1 Amid Debt Deal Chaos

Beyond Meat’s Shocking Collapse: BYND Stock Crashes Below $1 Amid Debt Deal Chaos

Beyond Meat shares plunged nearly 60% in one day, closing at $0.65 on Oct. 17 after a debt-for-equity swap triggered a flood of 316 million new shares. Founder and CEO Ethan Brown resigned from the board as analysts warned of a “death spiral.” The company reported Q2 revenue down 20% year-over-year and a net loss of $33 million. Cash reserves have dwindled to $117 million against $1.2 billion in debt.
18 October 2025
·
New Era Energy & Digital (NUAI) Skyrockets 185% on AI Data Center Buzz – Can the Tiny Stock Sustain the Hype?

New Era Energy & Digital (NUAI) Skyrockets 185% on AI Data Center Buzz – Can the Tiny Stock Sustain the Hype?

New Era Energy & Digital (NASDAQ: NUAI) closed at $4.55 on Oct. 17, up 44% in one day and 186% in two weeks after announcing progress on its 1-gigawatt AI data center in Texas. The company regained Nasdaq compliance, ended plans for share dilution, and rebranded from helium to AI infrastructure in August. NUAI remains pre-revenue, with $0.7 million in annual sales and steep losses. The stock is up 1300% from its 52-week low.
18 October 2025
····
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
Liberty Energy’s Rollercoaster: LBRT Surges on Earnings Despite Oilfield Headwinds

Liberty Energy (LBRT) Stock Soars 28% on Earnings Surprise – Can the Rally Last?

Liberty Energy Inc. shares surged 28% to $15.32 Friday after quarterly earnings, despite revenue falling 17% year-over-year and an adjusted net loss of $0.06 per share. The company posted a GAAP profit of $43 million due to one-off gains and raised its dividend by 13%. The stock remains well below its early-2025 highs after a steep year-to-date decline. Oilfield activity slowed sharply in 2025, hitting Liberty’s core business.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
AGI Race Sparks ‘Alien Intelligence’ Fears as Experts Clash – Tech Stocks Soar Amid Superintelligence Hype

AGI Race Sparks ‘Alien Intelligence’ Fears as Experts Clash – Tech Stocks Soar Amid Superintelligence Hype

Tech companies including OpenAI, DeepMind, and Meta are spending over $325 billion by 2025 to develop artificial general intelligence, with leaders predicting AGI could arrive this decade. Some researchers warn superintelligent AI could escape human control and pose existential risks. Nvidia shares surged after a $100 billion investment in OpenAI, while Alphabet’s market value nears $3 trillion amid the AI boom.
18 October 2025
···
1 … 1,259 1,260 1,261 1,262 1,263 … 1,328
Go toTop